Furthermore, these results also support earlier observations that TG2 expression is associated with the drug resistance and metastasis of breast cancer [6]–[8], hence TG2 represents a promising therapeutic target for the treatment of metastatic breast disease. This evidence concerns the gene TGM2 and breast carcinoma.